In this video, Dr Miguel Regueiro recaps highlights from his discussion on the positioning of sphingosine 1-phosphate receptor modulators for inflammatory bowel disease, presented at the Advances in Inflammatory Bowel Disease 2021 regional conference.

Miguel Regueiro, MD, is chair for Digestive Disease and Surgery Institute at Cleveland Clinic in Cleveland, Ohio.

TRANSCRIPT:

Dr. Miguel Regueiro:  Hello, everybody. I'm Dr. Miguel Regueiro. I'm Chair for Digestive Disease and Surgery Institute at Cleveland Clinic in Cleveland, Ohio. At AIBD Regionals, I discussed the positioning of S1P for inflammatory bowel disease.

We've had an exciting update that I reviewed, which was the inclusion now of ozanimod that is an FDA-approved medication for the treatment of moderate to severely active ulcerative colitis.

At AIBD Regionals, I reviewed not only S1P as a class, but specifically how we'll use ozanimod. It's new enough that probably most of us have not used this in clinical practice, and I have not actually had a chance to use it in clinical practice yet, but did use it in clinical trials.

The key take-home points with ozanimod and S1P in general, these are effective medicines for the treatment of ulcerative colitis. It's an oral small molecule, so it does not have immunogenicity, and it's taken as a pill, which is nice for patients. They can take it as a daily pill.

Although it does have some unique potential safety issues, generally, the safety looks quite good. What I mean by that is, for patients who have cardiac conduction abnormalities or cardiac abnormalities, we need to take special care. This is something that will probably get an EKG at baseline in our patients before placing them on ozanimod.

Otherwise, this seems to be an exciting new treatment option for the management of ulcerative colitis, and I hope you enjoyed my presentation. Thank you.